Related Experiment Video
Updated: May 31, 2026
07:30
Learning Modern Laryngeal Surgery in a Dissection Laboratory
Published on: March 18, 2020
Experience with supracricoid laryngectomy variants
Mohamed Rifai1, Mohamed Salah Hassouna, Ahmed El Farouk Abdel Fattah
1Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt. rifai29@yahoo.com
Head & Neck
|July 15, 2011
Summary
Supracricoid laryngectomy (SCL) offers an effective alternative to total laryngectomy (TL) for laryngeal cancer, achieving good oncological and functional outcomes. This organ-preserving surgery demonstrates high decannulation and voice intelligibility rates in select patients.
Area of Science:
- Otolaryngology
- Surgical Oncology
Background:
- Laryngeal cancer treatment often involves total laryngectomy (TL).
- Supracricoid laryngectomy (SCL) presents a potential organ-preserving alternative.
- Evaluating SCL outcomes is crucial for treatment planning.
Purpose of the Study:
- To assess the oncological and functional results of supracricoid laryngectomy (SCL).
- To compare SCL with total laryngectomy (TL) for laryngeal cancer management.
Main Methods:
- Retrospective analysis of 333 patients undergoing SCL for laryngeal squamous cell carcinoma.
- Data collected from May 1984 to May 2007 in an Egyptian hospital.
- Evaluation of surgical margins, survival rates, decannulation, stenosis, aspiration, and voice intelligibility.
Main Results:
- All surgical margins were tumor-free.
- The 5-year survival rate was 74%.
- 92.8% of patients were decannulated; voice intelligibility averaged 89%, highest with arytenoid preservation (95%).
- Complications included permanent stenosis (8 patients), persistent aspiration (7 patients), and 10 surgical-related deaths.
Conclusions:
- Supracricoid laryngectomy (SCL) is an effective organ-preserving oncological treatment for laryngeal cancer.
- Modifications allowing resection of both arytenoids are feasible in select cases.
- SCL provides favorable functional and oncological outcomes, making it a viable alternative to TL.
